Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 9/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3983669 | 0.97 | — | — | |
| SCHEMBL688634 | 0.92 | — | — | |
| SCHEMBL687673 | 0.86 | — | — | |
| SCHEMBL10443486 | 0.76 | ALDH1A1 (0.40) | EPHX1SIGMAR1ALDH1A1CES2CES1 | |
| SCHEMBL4592859 | 0.76 | ALDH1A1 (0.40) | EPHX1SIGMAR1ALDH1A1CES2CES1 | |
| SCHEMBL3732008 | 0.74 | ALDH1A1 (0.39) | EPHX1SIGMAR1ALDH1A1CES2CES1 | |
| SCHEMBL6649524 | 0.74 | SIGMAR1 (0.40) | EPHX1SIGMAR1ALDH1A1HIF1AKDM4E | |
| SCHEMBL1797462 | 0.74 | NOS2 (0.42) | EPHX1SIGMAR1ALDH1A1HIF1AKDM4E | |
| SCHEMBL8396542 | 0.74 | ALDH1A1 (0.39) | EPHX1SIGMAR1ALDH1A1CES2CES1 | |
| SCHEMBL3038206 | 0.74 | ALDH1A1 (0.39) | EPHX1SIGMAR1ALDH1A1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 892 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114929821-B | derivatized polyamino acids | CMC材料有限责任公司 | 2023-12-19 | — | — | CN | claimed |
| CN-114929821-A | Derivatized polyamino acids | CMC材料股份有限公司 | 2022-08-19 | — | — | CN | claimed |
| CN-114574157-A | General organic silicon pressure-sensitive adhesive with high peel strength and preparation method thereof | 广州布鲁奥申新材料科技有限公司 | 2022-06-03 | — | — | CN | claimed |
| US-9935269-B2 | Electroluminescence element | Konica Minolta, Inc. (JP) | 2018-04-03 | — | — | US | claimed |
| US-8034811-B2 | Hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2011-10-11 | — | — | US | claimed |
| EP-1697312-B1 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2011-07-20 | — | — | EP | claimed |
| US-20110060037-A1 | USE OF NPY Y5 RECEPTOR ANTAGONISTS FOR THE PREVENTION OF PSYCHO-STIMULANT AND OPIOID ABUSE | UNIVERSITY OF COPENHAGEN (DK) | 2011-03-10 | — | — | US | claimed |
| EP-2280703-A1 | USE OF NPY Y5 RECEPTOR ANTAGONISTS FOR THE PREVENTION OF PSYCHOSTIMULANT AND OPIOID ABUSE | Københavns Universitet (University Of Copenhagen) (DK) | 2011-02-09 | — | — | EP | claimed |
| WO-2009112033-A1 | USE OF NPY Y5 RECEPTOR ANTAGONISTS FOR THE PREVENTION OF PSYCHOSTIMULANT AND OPIOID ABUSE | KØBENHAVNS UNIVERSITET (UNIVERSITY OF COPENHAGEN) (DK) | 2009-09-17 | — | — | WO | claimed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | claimed |
| CN-1906155-A | Novel hydroxamic acid esters and pharmaceutical use thereof | LEO PHARMA AS (DK) | 2007-01-31 | — | — | CN | claimed |
| EP-1697312-A2 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | claimed |
| WO-2005054179-A2 | HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2005-06-16 | — | — | WO | claimed |
| EP-0601092-A1 | METHOD FOR THE SELECTION OF GENETICALLY TRANSFORMED CELLS AND COMPOUNDS FOR USE IN THE METHOD | Novartis AG (CH) | 1994-06-15 | — | — | EP | claimed |
| WO-1993005163-A1 | METHOD FOR THE SELECTION OF GENETICALLY TRANSFORMED CELLS AND COMPOUNDS FOR USE IN THE METHOD | SANDOZ LTD. (CH) | 1993-03-18 | — | — | WO | claimed |
| EP-0530129-A1 | Method for the selection of genetically transformed cells and compounds for use in the method | SANDOZ LTD. (CH) | 1993-03-03 | — | — | EP | claimed |
| US-5162362-A | Hypotensive agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-11-10 | — | — | US | claimed |
| US-5158959-A | Treatment of hypertension | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-10-27 | — | — | US | claimed |
| EP-0328160-A1 | Amino acid derivatives, process to prepare them, composition containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-16 | — | — | EP | claimed |
| EP-0278530-A2 | Amino acid derivatives, process for their preparation, agents containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-08-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | F9, F12, HDAC9 | EPHX1 201/4885SIGMAR1 2385/4885ALDH1A1 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.